Concepts (224)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Abortion, Induced | 18 | 2023 | 82 | 5.250 |
Why?
|
| Pregnancy | 34 | 2023 | 1503 | 2.290 |
Why?
|
| Contraception | 7 | 2023 | 57 | 2.280 |
Why?
|
| Robotics | 4 | 2023 | 43 | 2.150 |
Why?
|
| Contraception Behavior | 4 | 2020 | 31 | 1.710 |
Why?
|
| Abortion, Spontaneous | 2 | 2022 | 25 | 1.250 |
Why?
|
| Papillomavirus Vaccines | 4 | 2017 | 136 | 1.210 |
Why?
|
| Intrauterine Devices | 4 | 2020 | 18 | 1.190 |
Why?
|
| Hawaii | 20 | 2023 | 1878 | 1.090 |
Why?
|
| Postal Service | 2 | 2021 | 7 | 1.020 |
Why?
|
| Female | 43 | 2023 | 19873 | 1.010 |
Why?
|
| Abortifacient Agents | 2 | 2021 | 12 | 1.000 |
Why?
|
| Health Services Accessibility | 2 | 2021 | 531 | 0.980 |
Why?
|
| Young Adult | 22 | 2023 | 4012 | 0.980 |
Why?
|
| Contraceptive Agents, Female | 3 | 2020 | 23 | 0.950 |
Why?
|
| Telemedicine | 3 | 2021 | 163 | 0.950 |
Why?
|
| Adolescent | 20 | 2023 | 5035 | 0.930 |
Why?
|
| Gestational Age | 6 | 2019 | 190 | 0.890 |
Why?
|
| Uterine Hemorrhage | 4 | 2019 | 14 | 0.890 |
Why?
|
| Qualitative Research | 6 | 2023 | 393 | 0.890 |
Why?
|
| Fetal Research | 1 | 2022 | 4 | 0.870 |
Why?
|
| Fentanyl | 1 | 2022 | 7 | 0.870 |
Why?
|
| Home Childbirth | 1 | 2022 | 3 | 0.850 |
Why?
|
| Adult | 27 | 2023 | 11034 | 0.820 |
Why?
|
| Hypoxia-Ischemia, Brain | 1 | 2022 | 42 | 0.810 |
Why?
|
| Humans | 47 | 2023 | 34853 | 0.790 |
Why?
|
| Intrauterine Devices, Medicated | 2 | 2018 | 11 | 0.780 |
Why?
|
| Levonorgestrel | 2 | 2018 | 16 | 0.780 |
Why?
|
| Sexually Transmitted Diseases | 2 | 2019 | 165 | 0.750 |
Why?
|
| Pregnancy, Unplanned | 2 | 2020 | 28 | 0.730 |
Why?
|
| Fetal Blood | 3 | 2015 | 47 | 0.730 |
Why?
|
| Choice Behavior | 1 | 2020 | 75 | 0.700 |
Why?
|
| Social Values | 2 | 2016 | 30 | 0.700 |
Why?
|
| Insurance, Health | 3 | 2023 | 120 | 0.690 |
Why?
|
| Physicians | 1 | 2020 | 148 | 0.670 |
Why?
|
| Condoms | 1 | 2019 | 132 | 0.660 |
Why?
|
| Attitude to Health | 1 | 2021 | 311 | 0.660 |
Why?
|
| Insurance Coverage | 2 | 2015 | 99 | 0.650 |
Why?
|
| Seafood | 2 | 2015 | 19 | 0.630 |
Why?
|
| Laminaria | 1 | 2017 | 3 | 0.630 |
Why?
|
| Anesthesia, Obstetrical | 1 | 2017 | 6 | 0.630 |
Why?
|
| Postpartum Period | 1 | 2018 | 59 | 0.630 |
Why?
|
| Mercury | 2 | 2015 | 35 | 0.620 |
Why?
|
| Papillomavirus Infections | 3 | 2016 | 316 | 0.610 |
Why?
|
| Attitude of Health Personnel | 2 | 2017 | 186 | 0.610 |
Why?
|
| Reminder Systems | 1 | 2017 | 12 | 0.610 |
Why?
|
| Postnatal Care | 1 | 2017 | 12 | 0.600 |
Why?
|
| Family Planning Services | 2 | 2018 | 29 | 0.590 |
Why?
|
| Pregnancy Trimester, Second | 2 | 2017 | 16 | 0.570 |
Why?
|
| Family Practice | 2 | 2016 | 43 | 0.560 |
Why?
|
| Family Planning Policy | 1 | 2015 | 2 | 0.550 |
Why?
|
| Health Knowledge, Attitudes, Practice | 5 | 2017 | 790 | 0.550 |
Why?
|
| Oxytocin | 3 | 2022 | 24 | 0.540 |
Why?
|
| Pediatrics | 1 | 2015 | 66 | 0.510 |
Why?
|
| Diabetes, Gestational | 3 | 2023 | 46 | 0.510 |
Why?
|
| Medicaid | 1 | 2015 | 102 | 0.500 |
Why?
|
| Income | 1 | 2014 | 135 | 0.460 |
Why?
|
| Double-Blind Method | 4 | 2022 | 269 | 0.440 |
Why?
|
| Misoprostol | 6 | 2022 | 26 | 0.430 |
Why?
|
| Cesarean Section | 2 | 2011 | 53 | 0.420 |
Why?
|
| Balloon Occlusion | 1 | 2011 | 3 | 0.410 |
Why?
|
| Dilatation and Curettage | 1 | 2011 | 4 | 0.410 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2011 | 7 | 0.410 |
Why?
|
| United States | 7 | 2023 | 3894 | 0.390 |
Why?
|
| Feeding Behavior | 1 | 2014 | 418 | 0.380 |
Why?
|
| Oxytocics | 3 | 2019 | 8 | 0.370 |
Why?
|
| Analgesics | 2 | 2022 | 56 | 0.370 |
Why?
|
| Logistic Models | 4 | 2022 | 894 | 0.360 |
Why?
|
| Diet | 1 | 2014 | 747 | 0.320 |
Why?
|
| Blood Loss, Surgical | 2 | 2018 | 13 | 0.310 |
Why?
|
| Pain | 2 | 2022 | 249 | 0.310 |
Why?
|
| Mifepristone | 3 | 2022 | 33 | 0.300 |
Why?
|
| Patient Satisfaction | 2 | 2017 | 141 | 0.290 |
Why?
|
| Abortifacient Agents, Nonsteroidal | 3 | 2021 | 9 | 0.290 |
Why?
|
| Students, Medical | 2 | 2018 | 121 | 0.280 |
Why?
|
| Ibuprofen | 2 | 2022 | 33 | 0.270 |
Why?
|
| Magnetics | 2 | 2022 | 36 | 0.260 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2020 | 375 | 0.250 |
Why?
|
| Pregnancy in Adolescence | 2 | 2016 | 33 | 0.250 |
Why?
|
| Physical Phenomena | 1 | 2023 | 2 | 0.240 |
Why?
|
| Heating | 1 | 2023 | 4 | 0.240 |
Why?
|
| Body Temperature Regulation | 1 | 2023 | 8 | 0.240 |
Why?
|
| Elastomers | 1 | 2022 | 3 | 0.220 |
Why?
|
| Motion | 1 | 2022 | 26 | 0.220 |
Why?
|
| Fetal Tissue Transplantation | 1 | 2022 | 4 | 0.220 |
Why?
|
| Aborted Fetus | 1 | 2022 | 5 | 0.220 |
Why?
|
| Pelvic Pain | 1 | 2022 | 9 | 0.220 |
Why?
|
| Pregnancy Trimester, First | 1 | 2022 | 24 | 0.220 |
Why?
|
| Parturition | 1 | 2022 | 22 | 0.210 |
Why?
|
| Intraoperative Complications | 2 | 2019 | 18 | 0.210 |
Why?
|
| Male | 11 | 2022 | 18870 | 0.200 |
Why?
|
| Drug and Narcotic Control | 1 | 2021 | 10 | 0.200 |
Why?
|
| Abortifacient Agents, Steroidal | 1 | 2021 | 3 | 0.200 |
Why?
|
| United States Food and Drug Administration | 1 | 2021 | 22 | 0.200 |
Why?
|
| Confidentiality | 1 | 2021 | 26 | 0.200 |
Why?
|
| Child | 2 | 2022 | 2875 | 0.200 |
Why?
|
| Treatment Outcome | 2 | 2018 | 1349 | 0.200 |
Why?
|
| Contraceptive Agents | 1 | 2020 | 13 | 0.200 |
Why?
|
| Drug Delivery Systems | 1 | 2022 | 182 | 0.190 |
Why?
|
| Postoperative Complications | 2 | 2019 | 206 | 0.190 |
Why?
|
| Infant, Newborn | 2 | 2022 | 871 | 0.190 |
Why?
|
| Case-Control Studies | 2 | 2022 | 1056 | 0.190 |
Why?
|
| Sterilization, Tubal | 1 | 2020 | 3 | 0.190 |
Why?
|
| Electric Capacitance | 1 | 2019 | 6 | 0.180 |
Why?
|
| Textiles | 1 | 2019 | 4 | 0.180 |
Why?
|
| Foot | 1 | 2019 | 10 | 0.180 |
Why?
|
| Communication | 2 | 2017 | 170 | 0.170 |
Why?
|
| Data Collection | 1 | 2019 | 188 | 0.170 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2018 | 14 | 0.170 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2019 | 32 | 0.170 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2019 | 107 | 0.170 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2018 | 32 | 0.170 |
Why?
|
| Health Personnel | 1 | 2020 | 200 | 0.170 |
Why?
|
| Hemostatics | 1 | 2018 | 8 | 0.160 |
Why?
|
| Sodium Bicarbonate | 1 | 2017 | 8 | 0.160 |
Why?
|
| Middle Aged | 4 | 2021 | 9642 | 0.160 |
Why?
|
| Lidocaine | 1 | 2017 | 15 | 0.160 |
Why?
|
| Age Factors | 2 | 2018 | 1007 | 0.160 |
Why?
|
| Dilatation | 1 | 2017 | 3 | 0.150 |
Why?
|
| Delivery, Obstetric | 1 | 2017 | 38 | 0.150 |
Why?
|
| Decision Making | 1 | 2019 | 189 | 0.150 |
Why?
|
| Self-Examination | 1 | 2017 | 8 | 0.150 |
Why?
|
| Feasibility Studies | 1 | 2018 | 196 | 0.150 |
Why?
|
| Parents | 2 | 2016 | 288 | 0.140 |
Why?
|
| Pain Measurement | 1 | 2017 | 161 | 0.140 |
Why?
|
| Pamphlets | 1 | 2016 | 27 | 0.140 |
Why?
|
| Trust | 1 | 2017 | 119 | 0.140 |
Why?
|
| Electronic Health Records | 1 | 2017 | 65 | 0.140 |
Why?
|
| Sexual Partners | 1 | 2019 | 308 | 0.140 |
Why?
|
| Population Groups | 1 | 2016 | 56 | 0.140 |
Why?
|
| Cross-Sectional Studies | 4 | 2017 | 2561 | 0.140 |
Why?
|
| Family Relations | 1 | 2015 | 45 | 0.140 |
Why?
|
| Pilot Projects | 1 | 2018 | 628 | 0.130 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 964 | 0.130 |
Why?
|
| Family Characteristics | 1 | 2015 | 102 | 0.130 |
Why?
|
| Focus Groups | 1 | 2015 | 307 | 0.130 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2022 | 592 | 0.130 |
Why?
|
| Retrospective Studies | 5 | 2021 | 1961 | 0.120 |
Why?
|
| Philippines | 1 | 2014 | 72 | 0.120 |
Why?
|
| Pacific Islands | 1 | 2014 | 115 | 0.120 |
Why?
|
| Japan | 1 | 2014 | 296 | 0.120 |
Why?
|
| Vaccination | 1 | 2015 | 259 | 0.120 |
Why?
|
| Social Support | 1 | 2015 | 356 | 0.110 |
Why?
|
| Overweight | 1 | 2015 | 233 | 0.110 |
Why?
|
| Animals | 4 | 2023 | 14307 | 0.110 |
Why?
|
| Residence Characteristics | 1 | 2015 | 301 | 0.110 |
Why?
|
| Selenium | 1 | 2015 | 144 | 0.110 |
Why?
|
| Selenoproteins | 1 | 2015 | 151 | 0.110 |
Why?
|
| Obesity | 2 | 2017 | 965 | 0.110 |
Why?
|
| Vitamin D Deficiency | 1 | 2013 | 94 | 0.100 |
Why?
|
| Antineoplastic Agents | 1 | 2019 | 756 | 0.100 |
Why?
|
| Vitamin D | 1 | 2013 | 176 | 0.100 |
Why?
|
| Health Promotion | 1 | 2016 | 588 | 0.100 |
Why?
|
| Ultrasonography, Prenatal | 2 | 2021 | 33 | 0.090 |
Why?
|
| Counseling | 2 | 2023 | 105 | 0.090 |
Why?
|
| Pregnancy Outcome | 1 | 2010 | 90 | 0.090 |
Why?
|
| Neoplasms | 1 | 2018 | 1033 | 0.090 |
Why?
|
| Abortion, Legal | 1 | 2023 | 6 | 0.060 |
Why?
|
| Flowers | 1 | 2023 | 16 | 0.060 |
Why?
|
| Asia | 1 | 2023 | 74 | 0.060 |
Why?
|
| Electricity | 1 | 2022 | 9 | 0.060 |
Why?
|
| Oxycodone | 1 | 2022 | 4 | 0.050 |
Why?
|
| Acetaminophen | 1 | 2022 | 24 | 0.050 |
Why?
|
| Locomotion | 1 | 2022 | 91 | 0.050 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2021 | 4 | 0.050 |
Why?
|
| Microtechnology | 1 | 2021 | 5 | 0.050 |
Why?
|
| Biomimetics | 1 | 2021 | 10 | 0.050 |
Why?
|
| Aftercare | 1 | 2021 | 18 | 0.050 |
Why?
|
| Biomimetic Materials | 1 | 2021 | 23 | 0.050 |
Why?
|
| Equipment Design | 1 | 2021 | 127 | 0.050 |
Why?
|
| Contraceptives, Oral, Combined | 1 | 2020 | 12 | 0.050 |
Why?
|
| Analgesics, Opioid | 1 | 2022 | 176 | 0.050 |
Why?
|
| Survival Analysis | 1 | 2020 | 322 | 0.040 |
Why?
|
| Blood Volume | 1 | 2019 | 5 | 0.040 |
Why?
|
| Reference Values | 1 | 2019 | 204 | 0.040 |
Why?
|
| Biomedical Research | 1 | 2023 | 371 | 0.040 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2018 | 23 | 0.040 |
Why?
|
| Minority Groups | 1 | 2023 | 537 | 0.040 |
Why?
|
| Methylergonovine | 1 | 2018 | 3 | 0.040 |
Why?
|
| Vasopressins | 1 | 2018 | 12 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2019 | 288 | 0.040 |
Why?
|
| Gynecology | 1 | 2018 | 31 | 0.040 |
Why?
|
| Patient Care Planning | 1 | 2017 | 14 | 0.040 |
Why?
|
| Analysis of Variance | 1 | 2019 | 528 | 0.040 |
Why?
|
| Obstetrics | 1 | 2018 | 38 | 0.040 |
Why?
|
| Vacuum Extraction, Obstetrical | 1 | 2017 | 5 | 0.040 |
Why?
|
| Parity | 1 | 2017 | 46 | 0.040 |
Why?
|
| Education, Medical, Graduate | 1 | 2017 | 53 | 0.040 |
Why?
|
| Prevalence | 2 | 2013 | 1425 | 0.040 |
Why?
|
| Physician-Patient Relations | 1 | 2017 | 118 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 841 | 0.040 |
Why?
|
| Sex Education | 1 | 2016 | 29 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2016 | 136 | 0.040 |
Why?
|
| Community Networks | 1 | 2016 | 98 | 0.030 |
Why?
|
| Peer Group | 1 | 2016 | 138 | 0.030 |
Why?
|
| Health Surveys | 1 | 2017 | 358 | 0.030 |
Why?
|
| Program Development | 1 | 2016 | 225 | 0.030 |
Why?
|
| Time Factors | 1 | 2019 | 1681 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2016 | 316 | 0.030 |
Why?
|
| Fishes | 1 | 2015 | 48 | 0.030 |
Why?
|
| Placenta | 1 | 2015 | 91 | 0.030 |
Why?
|
| Adolescent Behavior | 1 | 2016 | 243 | 0.030 |
Why?
|
| Health Education | 1 | 2016 | 304 | 0.030 |
Why?
|
| Nonlinear Dynamics | 1 | 2013 | 30 | 0.030 |
Why?
|
| Lactation | 1 | 2013 | 38 | 0.030 |
Why?
|
| Sunlight | 1 | 2013 | 46 | 0.030 |
Why?
|
| Seasons | 1 | 2013 | 112 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2015 | 834 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 213 | 0.030 |
Why?
|
| Sexual Behavior | 1 | 2016 | 587 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2013 | 196 | 0.020 |
Why?
|
| Maternal Age | 1 | 2010 | 27 | 0.020 |
Why?
|
| Mice | 1 | 2021 | 5668 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2015 | 1152 | 0.020 |
Why?
|
| Micronesia | 1 | 2010 | 87 | 0.020 |
Why?
|
| Age Distribution | 1 | 2010 | 223 | 0.020 |
Why?
|
| Birth Weight | 1 | 2010 | 93 | 0.020 |
Why?
|
| Infant | 1 | 2013 | 1014 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2013 | 1003 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2013 | 1353 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2010 | 333 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2010 | 775 | 0.020 |
Why?
|
| Aged | 1 | 2016 | 6448 | 0.020 |
Why?
|
| Risk Factors | 1 | 2010 | 3414 | 0.010 |
Why?
|